Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,410.00

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by stock analysts at Cantor Fitzgerald from $1,350.00 to $1,410.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 20.48% from the company’s previous close.

Several other equities research analysts have also recently commented on the company. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Barclays raised their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday, May 21st. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,289.36.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,170.30 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The business has a fifty day simple moving average of $1,156.45 and a 200 day simple moving average of $1,045.49. The firm has a market cap of $1.10 trillion, a price-to-earnings ratio of 41.57, a P/E/G ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $2.22. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.69 billion. During the same quarter in the previous year, the company posted $6.31 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 34.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LLY. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $30,000. Maseco LLP lifted its holdings in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Finally, Aventus Investment Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after acquiring an additional 27 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat and raised outlook: Lilly reported $22.97 billion in second-quarter revenue, up approximately 48% year over year and well above the roughly $20.7 billion consensus estimate. Non-GAAP EPS of $8.38 also exceeded expectations of about $6.16. Management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and provided EPS guidance of $35.50-$36.50. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: GLP-1 demand remains the main catalyst: Sales of Mounjaro and Zepbound surged, together accounting for nearly two-thirds of quarterly revenue; Mounjaro sales reportedly rose 91%. Strong volume and international expansion are driving growth and helping Lilly widen its lead over Novo Nordisk in the obesity-drug market. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
• Positive Sentiment: Wall Street remains bullish: Analysts continue to see upside after the beat-and-raise quarter, with at least one major analyst increasing its price target. Coverage describes the results as strengthening Lilly’s long-term investment thesis. We’re increasing our Eli Lilly price target after another beat-and-raise quarter
• Positive Sentiment: Pipeline and competitive momentum: Lilly is expanding early access to experimental obesity treatment retatrutide, while investigational cancer drug olomorasib received an FDA breakthrough therapy designation. Novo Nordisk’s recent key miss further highlights Lilly’s competitive advantage in GLP-1 therapies.
• Neutral Sentiment: Key risks remain: Lilly’s growth is heavily concentrated in GLP-1 medicines, and manufacturing capacity could limit its ability to meet demand. At roughly $1.10 trillion in market value and a forward-looking premium valuation, the stock may remain sensitive to future execution, supply, and clinical results.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.